Mycobacterium ulcerans disease

Bulletin of the World Health Organization

Volumn 83, Issue 10, 2005, Pages 785-791

  Van Der Werf, Tjip S ^a   Stienstra, Ymkje ^a   Johnson, R Christian ^b   Phillips, Richard ^c   Adjei, Ohene ^d   Fleischer, Bernhard ^e   Wansbrough Jones, Mark H ^f   Johnson, Paul D R ^g   Portaels, Françoise ^h   Van Der Graaf, Winette T A ^a   Asiedu, Kingsley ⁱ  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Programme Nationale pour la Lutte Contre l'Ulcère de Buruli   (Benin)

^c KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^d KUMASI CENTRE FOR COLLABORATIVE RESEARCH IN TROPICAL MEDICINE   (Ghana)

^e Bernard Nocht Institute   (Germany)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h INSTITUTE OF TROPICAL MEDICINE   (Belgium)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Africa, Western; Meta analysis; Mycobacterium infections, atypical etiology epidemiology therapy; Mycobacterium ulcerans pathogenicity; Review literature

Indexed keywords

BCG VACCINE; DAPSONE; NITRITE; PHENYTOIN; RIFAMPICIN; STREPTOMYCIN;

DISEASE PREVALENCE; EPIDEMIOLOGY; LITERATURE REVIEW; META-ANALYSIS;

AFRICA; BACTERIAL TRANSMISSION; BACTERIOLOGY; BCG VACCINATION; BURULI ULCER; CONTRACTURE; DEBRIDEMENT; ENDEMIC DISEASE; FISH; HUMAN; INSECT; LIMB INJURY; MYCOBACTERIUM ULCERANS; PATHOGENESIS; PHYSIOTHERAPY; REVIEW; SEROLOGY; SKIN TRANSPLANTATION; SNAIL;

AFRICA, WESTERN; HUMANS; META-ANALYSIS; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS;

AFRICA; EASTERN HEMISPHERE; SUB-SAHARAN AFRICA; WEST AFRICA; WORLD;

GASTROPODA; HEXAPODA; MYCOBACTERIUM; MYCOBACTERIUM ULCERANS;

EID: 26944484811     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. van der Werf TS, van der Graaf WTA, Tappero JW, Asiedu K. Mycobacterium ulcerans infection. Lancet 1999;354:1013-8.
2. Johnson PD, Stinear TP, Hayman JA. Mycobacterium ulcerans - a mini-review. J Med Microbiol 1999;48:511-3.
3. Asiedu K, Scherpbier RW, Raviglione M. Buruli ulcer. Geneva: WHO. 2000;1-160. WHO/CDS/GBUI/2000.1 http://www.who.int/gtb-buruli/
4. Evans MR, Phillips R, Etuaful SN, Amofah G, Adomako J, Adjei O, et al. An outreach education and treatment project in Ghana for the early stage of Mycobacterium ulcerans disease. Trans R Soc Med Hyg 2003;97:159-60.
5. Stienstra Y, van der Graaf WTA, Asamoa K, van der Werf TS. Beliefs and attitudes towards Buruli ulcer Ghana. Am J Trop Med Hyg 2002;67:207-13.
6. Aujoulat I, Johnson C, Zinsou C, Guédénon A, Portaels F. Psychosocial aspects of health seeking behaviours of patients with Buruli ulcer in southern Benin. Trop Med Int Health 2003;8:750-9.
7. Teelken MA, Stienstra Y, Ellen DE, Quarshie E, Klutse E, et al. Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop 2003;88:51-6.
8. Stienstra Y, Dijkstra PU, Guédénon A, Johnson RC, Ampadu EO, Mensah T, et al. Development of a questionnaire assessing Buruli ulcer-induced functional limitation. Am J Trop Med Hyg 2004;70:318-22.
9. Stienstra Y, Dijkstra PU, van Wezel MJ, van Roest MH, Beets M, Zijlstra IJ, et al. Reliability and validity of the Buruli ulcer Functional Limitations Score (BUFLS) Questionnaire. Am J Trop Med Hyg 2005;72(4):449-52.
10. Asiedu K, Etuaful S. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 1998;59:1015-22.
11. Resolution WHA57.1. Surveillance and control of Mycobacterium ulcerans disease (Buruli ulcer). In: Fifty-seventh World Health Assembly, Geneva, 17-22 May 2004. Resolutions and decisions, Annexes. http://www.who.int/gb/e/e_wha57. html
12. MacCallum P, Tolhurst JC, Buckle G, Sissons HA. A new mycobacterial infection in man. J Path Bacteriol 1948;60:93-122.
13. Johnson PD, Veitch MG, Leslie DE, Flood PE, Hayman JA. The emergence of Mycobacterium ulcerans near Melbourne. Med J Aust 1996;164:76-8.
14. Hayman J. Postulated epidemiology of Mycobacterium ulcerans infection. Int J Epidemiol 1991;20:1093-8.
15. Portaels F. Epidemiology of mycobacterial diseases. Clin Derm 1995;13:207-22.
16. van Oye E, Ballion M. Faudra-t-il tenir compte d'une nouvelle affection à bacilles acido-résistants en Afrique? Ann Soc Belg Med Trop 1951;619-27.
17. Bafende AE, Phanzu MD, Imposo BB. Buruli ulcer in the Democratic Republic of Congo: epidemiology, presentation and outcome. Trop Doct 2004;34:82-4.
18. Clancey JK, Dodge OG, Lunn HF, Oduori ML. Mycobacterial skin ulcers in Uganda. Lancet 1961;ii:951-4.
19. Barker DJ. Buruli disease in a district of Uganda. J Trop Med Hyg 1971;74:260-4.
20. Amofah G, Bonsu F, Tetteh C, Okrah J, Asamoa K, Asiedu K, Addy J. Buruli ulcer in Ghana: results of a national case search. Emerg Infect Dis 2002;8:167-70.
21. Raghunathan PL, Whitney EA, Asamoa S, Stienstra Y, Taylor Jr TH, Amofah GK, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): Results from a Case-Control study in Ghana. Clin Infect Dis 2005;40:1445-53.
22. Marston BJ, Diallo MO, Horsburgh CR Jr, Diomande I, Saki MZ, Kanga JM, et al. Emergence of Buruli ulcer disease in the Daloa region of Côte d'Ivoire. Am J Trop Med Hyg 1995;52:219-24.
23. Debacker M, Aguiar J, Steunou C, Zinsou C, Meyers WM, Guedenon A, et al. Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001 Emerg Infect Dis 2004;10:1391-8.
24. Portaels F, Chemlal K, Eisen P, Johnson PD, Hayman JA, Nibble J, et al. Mycobacterium ulcerans in wild animals. Rev Sci Tech 2001;20:252-64.
25. Eddyani M, Ofori-Adjei D, Teugels G, De Weirdt D, Boakye D, Meyers WM, et al. Potential Role for Fish in Transmission of Mycobacterium ulcerans Disease (Buruli Ulcer): an Environmental Study. Appl Environ Microbiol 2004;70:5679-81.
26. Mitchell PJ, Jerrett IV, Slee KJ. Skin ulcers caused by Mycobacterium ulcerans in koalas near Bairnsdale, Australia. Pathology 1984;16:256-60.
27. Portaels F, Elsen P, Guimaraes-Peres A, Fonteyne PA, Meyers WM. Insects in the transmission of Mycobacterium ulcerans infection. Lancet 1999;353:986.
28. Marsollier L, Robert R, Aubry J, Saint Andre JP, Kouakou H, Legras P, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002;68:4623-8.
29. Marsollier L, Severin T, Aubry J, Merritt RW, Saint Andre JP, Legras P, et al. Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ Microbiol 2004;70:6296-8.
30. Meyers WM, Shelly WM, Connor DH, Meyers EK. Human Mycobacterium ulcerans infections developing at sites of trauma to skin. Am J Trop Med Hyg 1974;23:919-23.
31. Exner K, Lemperle G. Buruli-Ulkus - Nekrotisierende Infektion an der Hand eines Plastischen Chirurgen. Handchir Mikrochir Plast Chir 1987;19(4):230-2.
32. Debacker M, Zinsou C, Aguiar J, Meyers W, Portaels F. Mycobacterium ulcerans disease (Buruli ulcer) following human bite. Lancet 2002;360(9348):1830.
33. Stienstra Y, van der Graaf WTA, te Meerman GJ, The TH, de Leij LF, van der Werf TS. Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health 2001;6:1-9.
34. Duker AA, Carranza EJ, Hale M. Spatial dependency of Buruli ulcer prevalence on arsenic-enriched domains in Amansie West District, Ghana: implications for arsenic mediation in Mycobacterium ulcerans infection. Int J Health Geogr 2004;3:19.
35. Aiga H, Amano T, Cairncross S, Domako JA, Nanas OK, Coleman S. Assessing water-related risk factors for Buruli ulcer: a case-control study in Ghana. Am J Trop Med Hyg 2004;71:387-92.
36. Hayman J. Postulated epidemiology of Mycobacterium ulcerans infection. Int J Epidemiol 1991;20:1093-8.
37. Ross BC, Johnson PD, Oppedisano F, Marino L, Sievers A, Stinear T, et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol 1997;63:4135-8.
38. Ross BC, Marino L, Oppedisano F, Edwards R, Robins-Browne RM, Johnson PD. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997;35:1696-700.
39. van der Werf TS, van der Graaf WT, Groothuis DG, Knell AJ. Mycobacterium ulcerans infection in Ashanti region, Ghana. Trans R Soc Med Hyg 1989;83:410-3.
40. Hospers IC, Wiersma IC, Dijkstra PU, Stienstra Y, Etuaful SN, Ampadu EO, et al. Distribution of Buruli ulcer lesions over body surface area in a large case series in Ghana: uncovering clues for mode of transmission. Trans R Soc Med Hyg 2005;99:196-201.
41. Palomino JC, Portaels F. Effects of decontamination methods and culture conditions on viability of Mycobacterium ulcerans in the BACTEC system. J Clin Microbiol 1998;36:402-8.
42. Guimaraes-Peres A, Portaels F, de Rijk P, Fissette K, Pattyn SR, van Vooren J, et al. Comparison of two PCRs for detection of Mycobacterium ulcerans. J Clin Microbiol 1999;37:206-8.
43. Stienstra Y, van der Werf TS, Guarner J, Raghunathan PL, Spotts Whitney EA, van der Graaf WT, et al. Analysis of an IS2404-Based Nested PCR for Diagnosis of Buruli Ulcer Disease in Regions of Ghana Where the Disease Is Endemic. J Clin Microbiol 2003;41:794-7.
44. van der Werf TS, Stinear T, Stienstra Y, van der Graaf WT, Small PL. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003;362:1062-4.
45. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, et al. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci USA 2004;101:1345-9.
46. Trott KA, Stacy BA, Lifland BD, Diggs HE, Harland RM, Khokha MK, et al. Characterization of a Mycobacterium ulcerans-like infection in a colony of African tropical clawed frogs (Xenopus tropicalis). Comp Med 2004;54:309-17.
47. Mve-Obiang A, Lee RE, Umstot ES, Trott KA, Grammer TC, Parker JM, et al. A newly discovered mycobacterial pathogen isolated from lethal infections in laboratory colonies of Xenopus species produces a novel form of the M. ulcerans macrolide toxin, mycolactone. Infect Immun 2005;73(6):3307-12.
48. Hayman J, McQueen A. The pathology of Mycobacterium ulcerans infection. Pathology 1985;17:594-600.
49. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, Asamoa K, et al. Histopathologic Features of Mycobacterium ulcerans Infection. Emerg Infect Dis 2003;9:351-6.
50. Okenu DM, Ofielu LO, Easley KA, Guarner J, Spotts Whitney EA, Raghunathan PL, et al. Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic. Clin Diagn Lab Immunol 2004;11:387-91.
51. Stanford JL, Revill WD, Gunthorpe WJ, Grange JM. The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) 1975;74:7-16.
52. Gooding TM, Johnson PD, Smith M, Kemp AS, Robins-Browne RM. Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun 2002;70:5562-7.
53. Prévot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, et al. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun 2004;72:958-65.
54. Westenbrink BD, Stienstra Y, Huitema MG, Thompson WA, Klutse EY, Ampadu EO, et al. Cytokine responses in whole blood stimulation experiments of patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol 2005;12:125-9.
55. Scott JT, Johnson RC, Aguiar J, Debacker M, Kestens L, Guédénon A, et al. Schistosoma haematobium infection and Buruli ulcer. Emerg Infect Dis 2004;10:551-2.
56. Stienstra Y, van der Werf TS, van der Graaf WT, Secor WE, Kihlstrom SL, Dobos KM, et al. Buruli ulcer and schistosomiasis: no association found. Am J Trop Med Hyg 2004;71:318-21.
57. Uganda Buruli group. BCG vaccination against Mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet 1969;1:111-5.
58. Portaels F, Aguiar J, Debacker M, Guédénon A, Steunou C, Zinsou C, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004;72:62-5.
59. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, van Vloten F, et al. Dry-reagent-based PCR as a novel tool for laboratory confirmation of clinically diagnosed Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic. J Clin Microbiol 2005;43:271-6.
60. Amofah G, Asamoah S, Afram-Gyening C. Effectiveness of excision of preulcerative Buruli lesions in field situations in a rural district in Ghana. Trop Doct 1998;28:81-3.
61. Dega H, Robert J, Bonnafous P, Jarlier V, Grosset J. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2000;44:2367-72.
62. Marsollier L, Prévot G, Honoré N, Legras P, Manceau AL, Payan C, et al. Susceptibility of Mycobacterium ulcerans to a combination of amikacin/rifampicin. Int J Antimicrob Agents 2003;22:562-6.
63. Revill WD, Morrow RH, Pike MC, Ateng J. A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 1973;2:873-7.
64. Espey DK, Djomand G, Diomande I, Dosso M, Saki MZ, Kanga JM, et al. A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis 2002;6:60-5.
65. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005;49(8):3182-6.
66. Chauty A, et al. The role of antibiotics in the management of Buruli ulcer at the Pobe Center in Benin. In: Report of the 7th WHO Advisory Group Meeting on Buruli Ulcer, 8-11 March 2004, WHO headquarters, Geneva, Switzerland.
67. Meyers WM, Shelly WM, Connor DH. Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg 1974;23:924-9.
68. Krieg RE, Wolcott JH, Meyers WM. Mycobacterium ulcerans infection: treatment with rifampin, hyperbaric oxygenation, and heat. Aviat Space Environ Med 1979;50:888-92.
69. Adjei O, Evans MR, Asiedu A. Phenytoin in the treatment of Buruli ulcer. Trans R Soc Med Hyg 1998;92:108-9.
70. Phillips R, Adjei O, Lucas S, Benjamin N, Wansbrough-Jones M. Pilot randomized double-blind trial of treatment of Mycobacterium ulcerans disease (Buruli ulcer) with topical nitrogen oxides. Antimicrob Agents Chemother 2004;48:2866-70.